MC10’s BioStamp® Sensor Technology promises to revolutionize clinical researcher’s ability to assess real-world physiological data.
LEXINGTON, Mass. – November 1, 2017 (BUSINESS WIRE) MC10, Inc., the company developing wearable sensor systems for seamless healthcare data collection, today announced a strategic collaboration with LabCorp, a leading global life sciences company. As part of the collaboration, LabCorp has also made an equity investment into MC10. The companies’ collaboration will support the adoption of MC10’s proprietary technology for use by LabCorp’s Covance Drug Development business in clinical trials and research studies, with the potential to be adapted over time for use in patient testing and monitoring.
In March of 2016, MC10 released BioStampRC®, a physiological data capture system and the first product built with the company’s proprietary BioStamp® Sensor technology. Top universities and pharmaceutical companies have incorporated the BioStampRC system as a fundamental tool in clinical research studies aiming to better understand human health.
By allowing for continuous, mobile monitoring of physiological data with medical-grade precision, MC10’s technology shows promise in changing the way clinical trials are conducted, opening up trial participation to a broader pool of subjects and providing researchers with more precise information about subject response to new treatments. LabCorp’s Covance Drug Development business is exploring opportunities to incorporate the BioStampRC system into planned clinical trials. MC10’s vision is to change the way patients are treated, particularly for chronic conditions in cardiovascular and neurological diseases, by allowing physicians to monitor key markers of health while the patient remains at home or goes to work, providing more flexibility and convenience for those patients while freeing up hospital beds and clinic space for patients who truly need in-person monitoring and treatment.
“Our collaboration with LabCorp focusing first on Covance, will accelerate the delivery of MC10’s innovative digital health solutions to our shared customer base in the pharmaceutical industry. We are optimistic for the growing portfolio of projects that will leverage LabCorp’s differentiated diagnostic expertise and MC10’s medical-grade wearable systems to advance our mission of reshaping healthcare with digital solutions,” commented Ben Schlatka, Co-Founder and Senior Vice President of Corporate Development at MC10.
To launch the collaboration, Covance is supporting the adoption of the BioStamp system in research studies best suited for mobile monitoring of participating subjects. Covance’s expert trial management capabilities will maximize the potential of MC10’s seamless and configurable sensor system.
“LabCorp is very excited about the potential applications for MC10’s BioStamp technology in clinical trials and research,” said William (Bill) Hanlon, Ph.D., Chief Development Officer and head of Global Regulatory Affairs for Covance. “We are confident that our collaboration with the great team at MC10 will help to bring new medicines to patients faster, advancing our mission to improve health and improve lives.”
MC10 is a private company, backed by a strong syndicate of financial and strategic investors, that is improving human health through digital healthcare solutions. The company combines its proprietary ultra-thin, flexible body-worn sensors with advanced analytics to unlock health insights from physiological data. MC10 has received widespread recognition for its revolutionary technology and was recently named in Fast Company’s Most Innovative Companies in 2016 as a leader in healthcare. MC10 is headquartered in Lexington, MA. Visit MC10 online at www.mc10inc.com.
MC10®, BioStampRC® and the MC10 logo are registered marks owned by MC10, Inc.